Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.2.797

Cellular Mechanisms of a New Pyrazinone Compound that Induces Apoptosis in SKOV-3 Cells  

Wang, Guan (Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, Jilin University)
Jiang, Meng-Ying (Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, Jilin University)
Meng, Ying (Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University)
Song, Hong-Rui (Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University)
Shi, Wei (Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, Jilin University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.2, 2014 , pp. 797-802 More about this Journal
Abstract
We screened a small molecular library that was designed and independently synthesized in vitro and found a new drug (MY-03-01) that is active against ovarian cancer. We established that MY-03-01 effectively inhibited SKOV-3 cell survival in a dose-dependent manner, based on cell viability rates, and that it not only induced SKOV-3 apoptosis by itself, but also did so synergistically with paclitaxel. Secondly, when MY-03-01 was applied at $40{\mu}M$, its hemolytic activity was less than 10%, compared with the control, and there was almost no damage to nor mal cells at this concentration. In addition, we used DAPI staining and flow cytometry to show that MY-03-01 could significantly induce apoptosis of SKOV-3 cells. Finally, we found that MY-03-01 likely induced SKOV-3 apoptosis by activating caspase3 and caspase9 through the mitochondrial pathway.
Keywords
Apoptosis; flow cytometry; hemolytic activity; ovarian cancer; paclitaxel; small molecular inhibitor;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Rouzier R, Bergzoll C, Brun JL, et al (2010). The role of lymph node resection in ovarian cancer: analysis of the Surveillance, Epidemiology, and End Results (SEER) database. BJOG, 117, 1451-8.   DOI   ScienceOn
2 Sachdeva MS (1998). Drug targeting systems for cancer chemothe- erapy. Expert Opin Investig Drugs, 7, 1849-4.   DOI   ScienceOn
3 Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on prematurecacer deaths. CACancer J Clin, 61, 212-6.   DOI
4 Wagner U, du Bois A, Pfisterer J, et al (2007). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinumtaxane based therapya phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol, 105, 132-7.   DOI   ScienceOn
5 Wahl H, Tan L, Griffith K, Choi M, Liu JR (2007). Curcumin enhances nces Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol, 105, 104-2.   DOI   ScienceOn
6 Zamboni WC, Strychor S, Joseph E (2008). Tumor, tissue, and pl-asma pharma cokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bear-ing SKOV-3 human ovarian xenografts. Cancer Chemother Pharmacol, 62, 417-6.   DOI
7 Zhang Y, Ge Y, Chen Y, et al (2012). Cellular and molecular mechanisms of silibinin induces cell-cycle arrest and apoptosis on HeLa cells. Cell Biochem Funct, 30, 243-8.   DOI   ScienceOn
8 Metzger-Filho O, Moulin C, D'Hondt V (2010). First-line systemic treatment of ovarian cancer: a critical re'view of available eviden- ce and expectations for future directions. Curr Opin Oncol, 22, 513-0.   DOI   ScienceOn
9 du Bois A, Quinn M, Thigpen T, et al (2005). 2004 consensus stat- ements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian C-ancer Consensus Conference (GCIG OCCC 2004). Ann Oncol, 16, viii7-2.
10 McGuire WP, Hoskins WJ, Brady MF, et al (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patpatients with stage III and stage IV ovarian cancer. N Engl J Med, 334, 1-6.   DOI   ScienceOn
11 Rogalska A, Gajek A, Szwed M, Jozwiak Z, Marczak A (2011). T- he role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of do- xorubicin. Toxicol In Vitro, 25, 1712-0.   DOI   ScienceOn
12 Meng Y, Wang G, Li Y, et al (2013). Synthesis and biolo-gical evaluation of new pyrrolopyrazinone compounds as potential antitumor agents. Chin Chem Lett, 24, 619-1.   DOI   ScienceOn
13 Petrucci E, Pasquini L, Petronelli A, et al (2007). A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol, 105, 481-2.   DOI   ScienceOn
14 Piotrowska H, Myszkowski K Ziolkowska A, et al (2012). Resver- atrol analogue 3,4,4',5-tetramethoxystilbene inhibits growth, arr-ests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells. Toxicol Appl Pharmacol, 263, 53-0.   DOI   ScienceOn
15 Rogalska A, Marczak A, Gajek A, et al (2013). Induction of apopt-osis in human ovarian cancer cells by new anticancer compoun-ds, epothilone A and B. Toxicol In Vitro, 27, 239-9.   DOI   ScienceOn
16 Abuharbeid S, Apel J, Zugmaier G, et al (2005). Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol, 371, 141-1.   DOI   ScienceOn
17 Chauhan SC, Kumar D, Jaggi M (2009). Mucins in ovarian cancer diagnosis and therapy. J Ovarian Res, 12, 21-9.
18 Degterev A, Boyce M, Yuan J (2003). A decade of caspases. Onco- gene, 22, 8543-7.   DOI   ScienceOn
19 Descoteaux C, Brasseur K, Leblanc V, et al (2012). Design of novel tyrosinenitrogen mustard hybrid molecules active against uterine, ovarian and brea- st cancer cell lines. Steroids, 77, 403-2.   DOI   ScienceOn
20 Dejean LM, Martinez-Caballero S, Kinnally KW (2006). Is MAC the knife that cuts cytochrome c from mitochondria during apop-tosis? Cell Death Differ, 13, 1387-5.   DOI   ScienceOn